在第三阶段试验结果之后, 维里迪安疗法公司的股价下跌了30%以上. Viridian Therapeutics stock drops over 30% after Phase 3 trial results.

维里迪安治疗公司的股价在周一大幅下跌, 因为其药物elegorobart在甲状腺眼病第三阶段试验中达到主要终点. Shares of Viridian Therapeutics fell sharply Monday after its drug elegrobart met a primary endpoint in a Phase 3 trial for thyroid eye disease. 虽然治疗明显改善了与安慰剂相比眼睛膨胀率,但分析师指出结果远低于高期望,导致库存下降超过30%. While the treatment improved eye bulging rates significantly compared to placebo, analysts noted the results fell short of high expectations, causing the stock to drop over 30%.